GlobeNewswire Inc | Feb 5, 2021 07:00AM EST

February 05, 2021

NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.

Presentation Details:

Event Guggenheim Healthcare Talks 2021 Oncology DaysDate Friday, February 12, 2021Time 1:30 p.m. EST

Event SVB Leerink 10th Annual Global Healthcare ConferenceDate Wednesday, February 24, 2021Time: 10:00 a.m. EST

Live webcasts from the Guggenheim and SVB Leerink fireside chats will be accessible through the Investors section of the Companys website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website.

About Zentalis

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

For more information, please visitwww.zentalis.com. Follow Zentalis on Twitter at@ZentalisPand on LinkedIn atwww.linkedin.com/company/zentalis-pharmaceuticals.

Investor Contact:

Thomas HoffmannSolebury Trout1.646.378.2931thoffmann@soleburytrout.com

Media Contact:

Julia DeutschSolebury Trout1.646.378.2967jdeutsch@soleburytrout.com